Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US Post published:June 10, 2021 Post category:Press Release
Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group Post published:May 18, 2021 Post category:Press Release
Entheon Biomedical Corp. Provides Corporate Update Post published:May 14, 2021 Post category:Press Release
Entheon Biomedical Lists on OTCQB Venture Market Post published:May 5, 2021 Post category:Press Release
Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test Post published:April 6, 2021 Post category:Press Release
Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs Post published:March 3, 2021 Post category:Press Release
Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences Post published:February 24, 2021 Post category:Press Release
Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study Post published:February 22, 2021 Post category:Press Release
Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development Post published:February 16, 2021 Post category:Press Release
Entheon Biomedical Hires ClearTV Executive as VP of Digital Experience Entertainment Veteran Jonna Birgans to Oversee Digital and VR Content Development Post published:February 4, 2021 Post category:Press Release